Roche: new data confirm Tecentriq works.
(CercleFinance.com) - At a major industry meeting last weekend Swiss drugmaker Roche presented new data which showed the potential of its immunotherapy drug Tecentriq.
At the American Society of Clinical Oncology (ASCO) meeting, which is currently being held in Chicago, the company unveiled "promising" phase II results in combination with Avastin in advanced kidney cancer.
Another phase III trial, showed that a "promising clinical benefit" of the treatment beyond radiologic disease progression in advanced lung cancer.
Data suggests that Tecentriq has the potential to be used as a combination partner with cancer immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers, Roche said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
At the American Society of Clinical Oncology (ASCO) meeting, which is currently being held in Chicago, the company unveiled "promising" phase II results in combination with Avastin in advanced kidney cancer.
Another phase III trial, showed that a "promising clinical benefit" of the treatment beyond radiologic disease progression in advanced lung cancer.
Data suggests that Tecentriq has the potential to be used as a combination partner with cancer immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers, Roche said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.